Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors

References

• Baumann RP, Penketh PG, Ishiguro K, Shyam K, Zhu YL, Sartorelli AC. 2010. Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O6-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance. Biochemical Pharmacology 79:1553–15561.
   PubMed Web of Science ®Google Scholar
• Baumann RP, Seow HA, Shyam K, Penketh PG, Sartorelli AC. 2005. The antineoplastic efficacy of the prodrug CloretazineTM is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncology Research 15:313–325.
   PubMed Web of Science ®Google Scholar
• Baumann RP, Shyam K, Penketh PG, Remack JS, Brent TP, Sartorelli AC. 2004. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemotherapy Pharmacology 53:288–295.
   PubMed Web of Science ®Google Scholar
• Donnelly ET, Liu Y, Rockwell S. 2006. Efaproxiral (RSR13) plus oxygen breathing increases the therapeutic ratio of carboplatin in EMT6 mouse mammary tumors. Experimental Biology and Medicine 231:317–321.
   Web of Science ®Google Scholar
• Finch RA, Shyam K, Penketh PG, Sartorelli AC. 2001. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): A novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Research 61:3033–3038.
   PubMed Web of Science ®Google Scholar
• Frederick AM, Davis ML, Rice KP. 2009. Inhibition of human DNA polymerase β activity by the anticancer prodrug Cloretazine. Biochemical and Biophysical Research Communications 378:419–423.
   PubMed Web of Science ®Google Scholar
• Giles FJ. 2007. Bendamustine and cloretazine: Alkylators with sharply contrasting activity in AML. Leukemia & Lymphoma 48:1064–1066.
   PubMed Web of Science ®Google Scholar
• Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar M, Mufti G, O’Brien S. 2007. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Journal of Clinical Oncology 25:25–31.
   PubMed Web of Science ®Google Scholar
• Hahn GM, Rockwell S, Kallman RF, Gordon LF, Frindel E. 1974. Repair of potentially lethal damage in vivo in solid tumor cells after x-irradiation. Cancer Research 34:351–354.
   PubMed Web of Science ®Google Scholar
• Ishiguro K, Seow HA, Penketh PG, Shyam K, Sartorelli AC. 2006. Mode of action of the chloroethylating and carbamoylating moieties of the produrg cloretazine. Molecular Cancer Therapy 5:969–976.
   PubMed Web of Science ®Google Scholar
• Ishiguro K, Shyam K, Penketh PG, Sartorelli AC. 2005. Role of O6- alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine. Molecular Cancer Therapy 5:1755–1763.
   Google Scholar
• Ishiguro K, Zhu Y-L, Shyam K, Penketh PG, Baumann RP, Sartorelli AC. 2010. Quantitative relationship between guanine O6-alkyl lesions produced by OnriginTM and tumor resistance by O6-alkylguanine-DNA alkyltransferance. Biochemical Pharmacology 80:1317–1325.
   PubMed Web of Science ®Google Scholar
• Li SX, Sjolund A, Harris L, Sweasy JB. 2010. DNA repair and personalized breast cancer therapy. Environmental and Molecular Mutagenesis 51:897–908.
   PubMed Web of Science ®Google Scholar
• Moulder JE, Rockwell S. 1987. Tumor hypoxia: Its impact on cancer therapy. Cancer and Metastasis Reviews 5:313–341.
   PubMed Web of Science ®Google Scholar
• Murren J, Modiano M, Kummar S, Clairmont C, Egorin M, Chu E, Sznol M. 2005. A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer. Investigational New Drugs 23:123–135.
   PubMed Web of Science ®Google Scholar
• Paz MM, Ladwa S, Champeil E, Liu Y, Rockwell S, Boamah EK, Bargonetti J, Callahan J, Roach J, Tomasz M. 2008. Mapping DNA adducts of mitomycin C and decarbamoyl mitomycin C in cell lines using liquid chromatography electrospray tandem mass spectrometry. Chemical Research Toxicology 21:2370–2378.
   PubMed Web of Science ®Google Scholar
• Penketh PG, Shyam K, Sartorelli AC. 2000. Comparison of DNA lesions produced by tumor-inhibitory 1,2-Bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochemical Pharmacology 59:283–291.
   PubMed Web of Science ®Google Scholar
• Penketh PG, Shyam K, Baumann RP, Remack JS, Brent TP, Sartorelli AC. 2004. 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Direct inhibition of O6- alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemotherapy and Pharmacology 53:279–287.
   PubMed Web of Science ®Google Scholar
• Penketh PG, Baumann RP, Ishiguro K, Shyam K, Seow HA, Sartorelli AC. 2008. Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species. Leukemia Research 32:1546–1553.
   PubMed Web of Science ®Google Scholar
• Ray GR, Hahn GM, Bagshaw MA, Kurkjian S. 1973. Cell survival and repair of plateau-phase cultures after chemotherapy; relevance to tumor therapy and to the in vitro screening of new agents. Cancer Chemotherapy Reports 57:473–475.
   PubMedGoogle Scholar
• Rice KP, Penketh PG, Shyam K, Sartorelli AC. 2005. Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs CloretazineTM and BCNU. Biochemical Pharmacology 69:1463–1472.
   PubMed Web of Science ®Google Scholar
• Rockwell S. 1977. In vivo-in vitro tumor systems: New model for studying the response of tumors to therapy. Laboratory Animal Science 27:831–851.
   PubMedGoogle Scholar
• Rockwell S, Dobrucki IT, Kim EY, Vu V. 2009. Hypoxia and radiation therapy: Past history, ongoing research, and future promise. Current Molecular Medicine 9:442–458.
   PubMed Web of Science ®Google Scholar
• Rockwell S, Hughes CS. 1994. Effects of mitomycin C and porfiromycin on exponentially growing and plateau phase cultures. Cell Proliferation 27:153–163.
   PubMed Web of Science ®Google Scholar
• Rockwell S, Kallman RF, Fajardo LF. 1972. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. Journal of the National Cancer Institute 49:735–749.
   PubMedGoogle Scholar
• Rockwell S, Liu Y. 2010. Aplidin as a potential adjunct to radiation therapy: In vitro studies. International Journal of Radiation Biology 86:63–70.
   PubMed Web of Science ®Google Scholar
• Shyam K, Penketh PG, Loomis RH, Rose WC, Sartorelli AC. 1996. Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazines. Journal of Medicinal Chemistry 39:796–801.
   PubMed Web of Science ®Google Scholar
• Steel GG. 1979. Terminology in the description of drug-radiation interactions. International Journal of Radiation Oncology Biology and Physics 5:1145–1150.
   PubMed Web of Science ®Google Scholar
• Steensma DP. 2010. Novel therapies for myelodysplastic syndromes. Hematology and Oncology Clinics of North America 24:423–441.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Lazo JS, Sartorelli AC. 1981. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Research 41:73–81.
   PubMed Web of Science ®Google Scholar
• Twentyman PR, Bleehen NM. 1975. Changes in sensitivity to cytotoxic agents occurring during the life history of monolayer cultures of a mouse tumour cell line. British Journal of Cancer 31:417–423.
   PubMed Web of Science ®Google Scholar
• Vey N, Giles F. 2010. Laromustine (cloretazine). Expert Opinions in Pharmacotherapy 11:657–667.
   PubMed Web of Science ®Google Scholar